Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma (Q57028105)

From Wikidata

Jump to navigation Jump to search

scientific article published on 04 October 2018

edit

Language	Label	Description	Also known as
English	Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma	scientific article published on 04 October 2018

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

title

Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

main subject

chemotherapy

1 reference

based on heuristic

inferred from title

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author

Cary P Gross

series ordinal

4

object named as

Cary P Gross

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

Amy J. Davidoff

series ordinal

3

object named as

Amy J Davidoff

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

author name string

Scott F Huntington

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

Gottfried von Keudell

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

Sapna A Prasad

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

language of work or name

English

0 references

publication date

4 October 2018

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

published in

Journal of Clinical Oncology

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

page(s)

JCO1800122

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

cites work

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medicare beneficiaries' costs of care in the last year of life

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medicare program expenditures associated with hospice use.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of Hodgkin lymphoma in relapse after autologous stem cell transplant

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Limits on Medicare's ability to control rising spending on cancer drugs

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How I treat relapsed and refractory Hodgkin lymphoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economics of hematopoietic cell transplantation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indication-specific pricing for cancer drugs

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overspending driven by oversized single dose vials of cancer drugs

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fine-Tuning the Treatment of Hodgkin's Lymphoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Economics of Indication-Based Drug Pricing.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PET-adapted therapy for advanced Hodgkin lymphoma - systematic review

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30285558

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1200/JCO.18.00122

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

PMC publication ID

6241679

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

PubMed publication ID

30285558

1 reference

stated in

Europe PubMed Central

PMC publication ID

6241679

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30285558%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 April 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57028105&oldid=2242966463"